All Posts

Feb 2025 Being selected for Editor’s Choice underscores the originality and scientific significance of this research within the field of headache medicine. The International Headache Society has recognized the paper titled “Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice,” authored by E. Zorrilla and colleagues, as the Cephalalgia Editor’s Choice for February 2025 . The study investigates the effects of combined CBD and THC

Sep 2024 The $2.9M follows grant from the National Institute on Drug Abuse enables Delphian to use its Seed Financing toward a phase 1 clinical trial. Last week, the U.S. National Institutes of Health awarded us a $2.9M SBIR Grant toward developing S1-220, our patented, optimized CBD:THC formulation to treat migraine, one of the world's largest diseases. This has a number of very exciting implications. First, this new $2.9M NIH grant will take us through FDA Investigational N

May 2024 Delphian Tx has secured $2.7M in seed funding to advance its lead candidate, S1-221, an optimized combination of CBD:THC to treat migraine, into phase 1 clinical trials in 2025. Delphian Therapeutics is pleased to announce it has closed a $2.7M Seed Round of funding to advance its patented CBD:THC combination therapeutic into phase 1 clinical trials. Despite the introduction of new classes of therapeutics in recent years, migraine remains one of the world's largest,